Improving MEKC–ESI–MS–MS Analysis of Synthetic Cathinones
A team of scientists based in the Czech Republic has developed a micellular electrokinetic chromatography method coupled with tandem mass spectrometry (MEKC–ESI–MS–MS) that uses salts of perfluorocarboylic acid as the volatile background electrolyte (BGE). The method was applied to the determination of 12 drugs from the class of synthetic cathinones in urine samples. According to the paper published in the Journal of Chromatography A, the BGE used to form micelles did not affect the electron ionization efficiency of MS. (1)
Photo Credit: Getty Images/Yagi Studio
A team of scientists based in the Czech Republic has developed a micellular electrokinetic chromatography method coupled with tandem mass spectrometry (MEKC–ESI–MS–MS) that uses salts of perfluorocarboylic acid as the volatile background electrolyte (BGE). The method was applied to the determination of 12 drugs from the class of synthetic cathinones in urine samples. According to the paper published in the Journal of Chromatography A, the BGE used to form micelles did not affect the electron ionization efficiency of MS.1
Screening of biological samples is normally performed using either liquid chromatography or gas chromatography coupled with mass spectrometry, but capillary electrophoresis is another powerful technique for drug screening that is often side-lined. Lead author Vítezslav Maier told The Column: “Capillary electrophoresis connected with mass spectrometry using the electrospray ionization interface has one important disadvantage. The non-volatile components of the running electrolyte, which are normally used in the CE, cannot be used in MS detection, and the optimization of the separation of structurally close and related compounds such as the synthetic cathinones is very difficult. But we observed that some perfluorocarboxylic acids and some perfluorocarboxylic acids and their salts can create volatile micelles which could be used for the separation of the structurally related compounds from the cathinone family without decreasing of the electrospray ionization efficiency. Thus, the detection limits are comparable with LC–MS.”
Blank urine samples and urine spiked with cathinones were analyzed using MEKC–ESI–MS–MS. Solid-phase extraction (SPE), used as clean-up step prior to analysis with ammonium salt of perfluorooctanoic acid, was used as the volatile BGE. According to the paper, the approach did not require sample derivatization and derived LOD values were comparable to GC–MS methods.
When asked about future work, Maier told The Column: “Currently, we are working on the separation of a second wide and new group of drugs — synthetic cannabinoids. We solved the separation of several synthetic cannabinoids and their metabolites by supercritical fluid chromatography and also by capillary electrophoresis with tandem mass spectrometry. Nowadays we make some pilot analyses of the real samples.”
— B.D.
Reference
M. Svidrnoch, L. Lnenícková, I. Válka, P. Ondra, and V. Maier, Journal of Chromatography A1356, 258–265 (2014).
This story originally appeared in The Column. Click here to view that issue.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
Inside the Laboratory: The Richardson Group at the University of South Carolina
November 20th 2024In this edition of “Inside the Laboratory,” Susan Richardson of the University of South Carolina discusses her laboratory’s work with using electron ionization and chemical ionization with gas chromatography–mass spectrometry (GC–MS) to detect DBPs in complex environmental matrices, and how her work advances environmental analysis.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
Infographic: Be confidently audit ready, at any time and reduce failures in pharma QC testing
November 20th 2024Discover how you can simplify the audit preparation process with data integrity dashboards that provide transparency to key actions, and seamlessly track long-term trends and patterns, helping to prevent system suitability failures before they occur with waters_connect Data Intelligence software.
Critical Role of Oligonucleotides in Drug Development Highlighted at EAS Session
November 19th 2024A Monday session at the Eastern Analytical Symposium, sponsored by the Chinese American Chromatography Association, explored key challenges and solutions for achieving more sensitive oligonucleotide analysis.
